Screener
PTC Therapeutics PTCT Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by PTC Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: PTC Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:32 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001070081-26-000012
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Sale of marketable securities- available for sale | 376,359 | 136,750 |
| Sale of marketable securities- equity investments | 9,885 | 8,896 |
| Acquisition of product rights and licenses | (156) | (808) |
| Net cash used in investing activities | $(93,736) | $(184,360) |
| Cash flows from financing activities | ||
| Proceeds from exercise of options | $6,403 | $15,751 |
| Payments on contingent consideration obligation | — | (6,341) |
| Net cash provided by financing activities | $6,403 | $9,410 |
Item 1. Financial Statements (unaudited)
FAQ
- What is PTC Therapeutics's investing cash flow?
- PTC Therapeutics (PTCT) reported investing cash flow of -$93.74M in Q1 2026.
- How has PTC Therapeutics's investing cash flow changed year-over-year?
- PTC Therapeutics's investing cash flow increased by 49.2% year-over-year, from -$184.36M to -$93.74M.
- What is the long-term trend for PTC Therapeutics's investing cash flow?
- Over 4 years (2021 to 2025), PTC Therapeutics's investing cash flow has grown at a 42.2% compound annual growth rate (CAGR), from $219.18M to -$895.99M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about PTC Therapeutics's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude